BriaCell announces clinical data from its Phase 2 trial with Bria-IMT regimen

BriaCell Therapeutics report preliminary disease control rate of 61% in evaluable Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT regimen – the same formulation being used in BriaCell’s open pivotal Phase 3 study. Additionally, a disease control rate of 50% was reported in similarly treated evaluable patients who had failed prior antibody-drug conjugate, ADC, therapy. “We are beyond excited by the clinically significant disease control data we are seeing in this group of very difficult-to-treat patients,” stated Dr. William V. Williams, BriaCell’s President and CEO. “This data provides further encouragement to us as we continue our pivotal Phase 3 study enrollment. Our highest priority is to provide both survival and quality of life benefits to patients fighting a very deadly disease in a cohort with typically only a few months to live. Bria-IMT checks both boxes as no patients have discontinued our therapy due to treatment related serious side effects. We are closely monitoring the data and feedback we receive from our expert clinical team and the study participants, and look forward to sharing additional clinical data in the coming months.”